Mastermind Session: Beyond One Isotope, One Platform: Designing Radiohybrid Radiopharmaceuticals for the Alpha & Beta Era

11:30 am - Thursday 3rd December 2026

Leveraging radiohybrid technology to enable both alpha- and beta-emitting therapeutic strategies from a single targeting platform
Optimising pharmacokinetics and biodistribution to improve tumour retention whilst reducing off-target exposure
Selecting the right therapeutic radionuclide to maximise clinical impact across different stages of disease